Rogan, Psychedelics, and Schedule III: Trump’s White House Signals a Historic Shift in Drug Policy
In what may become one of the most culturally significant drug policy moments in modern American history, podcast giant Joe Rogan reportedly joined President Donald Trump during a White House event last week tied to a groundbreaking federal push toward psychedelic medical research and accelerated cannabis reform.
The moment sent shockwaves across both the psychedelic and cannabis industries, further blurring the lines between counterculture, medicine, politics, and mainstream America.
While rumors initially exploded online claiming Trump had fully “descheduled marijuana,” the actual developments were more nuanced — but still historic.
On April 18, 2026, Trump signed a major executive order directing federal agencies to accelerate research and approval pathways for psychedelic therapies, including psilocybin, ibogaine, MDMA, and related compounds being studied for PTSD, depression, addiction, and traumatic brain injury.
The White House action was heavily influenced by military veterans, mental health advocates, Health Secretary Robert F. Kennedy Jr., and public figures like Joe Rogan, who has spent years publicly discussing psychedelics as transformative tools for trauma recovery and consciousness exploration.
During the signing event, Trump openly criticized federal agencies for “slow-walking” marijuana rescheduling efforts, signaling growing frustration within the administration over delays surrounding cannabis reform.
Days later, the administration signaled support for accelerated Schedule III marijuana reform following announcements from the Department of Justice and Attorney General leadership supporting the ongoing federal rescheduling process. The move comes ahead of the DEA’s highly anticipated June 29 hearing, where federal officials are expected to review testimony and recommendations tied to marijuana’s potential reclassification under the Controlled Substances Act. A final federal decision is widely expected before mid-July.
The change does not fully legalize cannabis federally, nor does it completely remove marijuana from the Controlled Substances Act. Recreational cannabis technically remains federally illegal.
However, the Schedule III shift dramatically changes the economics and legitimacy of the cannabis industry.
For years, cannabis businesses have been crushed by IRS Code 280E, a federal tax rule preventing marijuana operators from taking normal business deductions because cannabis remained classified alongside heroin and LSD as a Schedule I narcotic.
Schedule III changes much of that equation.
The move could:
expand medical cannabis research
reduce crushing tax burdens
attract institutional investment
improve banking confidence
accelerate pharmaceutical and FDA-backed cannabis studies
further legitimize state medical marijuana programs.
For cannabis investors, operators, and entrepreneurs, the White House developments signaled something even larger: the federal government may finally be entering the post-prohibition era.
For psychedelic advocates, the symbolism was equally staggering.
Only a few years ago, substances like psilocybin and ibogaine were politically untouchable in Washington. Now, discussions involving psychedelic therapies are taking place inside the Oval Office itself — backed by veterans groups, medical researchers, Silicon Valley investors, and some of the biggest podcast voices in the world.
Joe Rogan’s presence at the White House underscored how dramatically the cultural landscape has shifted.
What was once fringe counterculture conversation is now becoming federal policy discussion.
And while full federal legalization of marijuana has not yet occurred, many industry observers believe the combination of psychedelic reform, Schedule III cannabis reclassification, and mounting public support could represent the beginning of the largest American drug policy transformation since the Nixon-era War on Drugs began more than 50 years ago.
